美股异动 推出下一代癌症免疫治疗平台 HCW Biologics(HCWB.US)暴涨近70%

Core Viewpoint - HCW Biologics (HCWB.US) experienced a nearly 70% surge in stock price, reaching $5.81, following the announcement of a second-generation immunotherapy drug based on Pembrolizumab targeting solid tumors, particularly pancreatic and ovarian cancers [1] Company Summary - HCW Biologics has developed a novel proprietary TRBC product discovery and development platform technology for its new immunotherapy drug [1] - The company highlighted that immune checkpoint inhibitors (ICIs), introduced in cancer treatment since 2011, are considered groundbreaking therapies but have shown a lack of immune cell co-stimulation activity, which diminishes their anti-tumor efficacy [1]